Ageing and Cancer Research & Treatment (ACRT) is pleased to announce the establishment of an official partnership with Shenzhen University Medical School (SZUMS).
The 16th International Symposium on DNA Damage Response & Human Disease (isDDRHD-2025) was successfully held in Qingdao, China, from October 17 to 20, 2025. Hosted by the State Key Laboratory of Microbial Technology at Shandong University, the symposium brought together world-leading experts and young investigators to discuss the latest advances in DNA damage response (DDR), genomic stability, ageing, and cancer. As an Academic Partner, Ageing and Cancer Research & Treatment (ACRT) proudly supported this landmark scientific event.
To further engage youth researchers and drive the innovative development of Ageing and Cancer Research & Treatment (ACRT), we are excited to officially launch the recruitment for the ACRT Youth Editorial Board! We sincerely invite outstanding youth scholars with demonstrated research expertise and genuine academic enthusiasm to join our team.
On August 28, 2025, at 10:00 PM (Beijing Time), Ageing and Cancer Research & Treatment (ACRT) convened its first monthly online Editorial Roundtable for Editors-in-Chief and Associate Editors.
Ageing and Cancer Research & Treatment (ACRT) is pleased to announce the appointment of Professor Xingzhi Xu and Professor Baohua Liu from Shenzhen University as the new Editors-in-Chief. Their leadership marks a significant step forward in the journal’s mission to advance cutting-edge research in the intersecting fields of ageing, cancer biology, and translational medicine.
On June 17, 2025, the Editorial Office of Ageing and Cancer Research & Treatment (ACRT) had the honor of interviewing Professor Hans-Georg Rammensee, a distinguished Advisory Editor of the journal and a globally recognized expert in tumor immunology from the University of Tübingen, Germany.
On April 25, 2025, Ageing and Cancer Research & Treatment (ACRT) held its held its first webinar, titled "Immunosuppressive Tumor Microenvironment Mediated by Myeloid-Derived Suppressor Cells and their Targeting". The event drew over 13,000 international viewers, underscoring the growing interest in this critical area of cancer research.
On February 19, 2025, the Editorial Office of Ageing and Cancer Research & Treatment (ACRT) had the honor of interviewing Professor Per Thor Straten, Co-Editor-in-Chief of ACRT and a distinguished expert in tumor immunology at Herlev University Hospital in Copenhagen, Denmark. During the interview, Prof. Thor Straten shared valuable insights into his career, the future of T-cell-based immunotherapies, and his vision for the journal.
On February 11, 2025, the Editorial Office of Ageing and Cancer Research & Treatment (ACRT) had the privilege of interviewing Professor Guido Kroemer, a world-renowned expert in aging and cancer research from Université de Paris Cité, France.
My own research career began in the Department of Surgery, Cambridge University, UK in transplantation immunology, facing the problems of immunosuppression to prevent organ rejection and attempts to prevent this by tissue matching, pharmacological agents and immunological tolerance induction.
